Cristina Esquinas1,2, Maria A Ramon3,4,5, Alexa Nuñez3, Jesús Molina6, José A Quintano7, Miguel Roman-Rodríguez8, Karlos Naberan9, Carl Llor10, Carlos Roncero11, Marc Miravitlles3,5, Miriam Barrecheguren3. 1. Department of Pneumology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. crise4@hotmail.com. 2. Public Health, Mental, Maternal and Child Health Nursing Departament, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. crise4@hotmail.com. 3. Department of Pneumology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain. 4. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 6. Dirección Asistencial Oeste, Centro de Salud Francia, Madrid, Spain. 7. Centro de Salud Lucena, Córdoba, Spain. 8. Primary Health Care Center Son Pisà, IB-Salut, Palma de Mallorca, Spain. 9. Centro de Salud Fuentes de Ebro, Saragossa, Spain. 10. Primary Care Centre Via Roma, Barcelona, Spain. 11. Psychiatric Service, University of Salamanca Health Care Complex, Institute of Biomedicine of Salamanca, University of Salamanca, Salamanca, Spain.
Abstract
PURPOSE: Impaired health-related quality of life (HRQoL) is associated with poor health outcomes in chronic obstructive pulmonary disease (COPD). The aim of this study was to determine health utilities in patients with COPD and to identify the variables with the greatest impact. METHODS: This is a pooled analysis of data from 4 observational studies performed in stable COPD patients. Evaluation of patient HRQoL utilities was performed using the Spanish version of the self-administered EuroQoL 5 Dimensions (EQ-5D) questionnaire. EQ-5D utilities were described and compared according to several markers of disease severity. RESULTS: 6198 patients reported a mean (SD) EQ-5D index of 0.67 (0.26). A linear dose response relationship between EQ-5D utility and modified Medical Research Council (mMRC) score, forced expiratory volume in one 1 s (% predicted), COPD hospital admissions in the previous year, self-reported daily walking time, Charlson index, body mass index, obstruction, dyspnoea and exacerbation (BODEx) index, COPD assessment test (CAT), hospital anxiety and depression scale was observed (p for trend < 0.001). In multivariate analysis, patients reporting lower utility values were those with more dyspnoea, more comorbidities, using long-term oxygen therapy, with previous hospitalisations due to a COPD exacerbation and higher (worse) CAT score. CONCLUSION: HRQoL measures such as EQ-5D can assist clinicians to understand the impact of respiratory disease on COPD patients.
PURPOSE: Impaired health-related quality of life (HRQoL) is associated with poor health outcomes in chronic obstructive pulmonary disease (COPD). The aim of this study was to determine health utilities in patients with COPD and to identify the variables with the greatest impact. METHODS: This is a pooled analysis of data from 4 observational studies performed in stable COPDpatients. Evaluation of patient HRQoL utilities was performed using the Spanish version of the self-administered EuroQoL 5 Dimensions (EQ-5D) questionnaire. EQ-5D utilities were described and compared according to several markers of disease severity. RESULTS: 6198 patients reported a mean (SD) EQ-5D index of 0.67 (0.26). A linear dose response relationship between EQ-5D utility and modified Medical Research Council (mMRC) score, forced expiratory volume in one 1 s (% predicted), COPD hospital admissions in the previous year, self-reported daily walking time, Charlson index, body mass index, obstruction, dyspnoea and exacerbation (BODEx) index, COPD assessment test (CAT), hospital anxiety and depression scale was observed (p for trend < 0.001). In multivariate analysis, patients reporting lower utility values were those with more dyspnoea, more comorbidities, using long-term oxygen therapy, with previous hospitalisations due to a COPD exacerbation and higher (worse) CAT score. CONCLUSION: HRQoL measures such as EQ-5D can assist clinicians to understand the impact of respiratory disease on COPDpatients.
Entities:
Keywords:
CAT; COPD; EQ-5D; Health-Related Quality of Life
Authors: Antònia Domingo-Salvany; Rosa Lamarca; Montserrat Ferrer; Judith Garcia-Aymerich; Jordi Alonso; Miquel Félez; Ahmad Khalaf; Ramon M Marrades; Eduard Monsó; Joan Serra-Batlles; Josep M Antó Journal: Am J Respir Crit Care Med Date: 2002-09-01 Impact factor: 21.405
Authors: A H Briggs; H A Glick; G Lozano-Ortega; M Spencer; P M A Calverley; P W Jones; J Vestbo Journal: Eur Respir J Date: 2009-08-28 Impact factor: 16.671
Authors: Carlos Martinez Rivera; Joaquín Costan Galicia; Bernardino Alcázar Navarrete; Cayo Garcia-Polo; Luis Alberto Ruiz Iturriaga; Alberto Herrejón; Jose Antonio Ros Lucas; Patricia García-Sidro; Gema Tirado-Conde; Jose Luis López-Campos; Sagrario Mayoralas Alises; Javier de Miguel-Díez; Cristina Esquinas; Marc Miravitlles Journal: Lung Date: 2016-03-01 Impact factor: 2.584
Authors: Maria A Ramon; Cristina Esquinas; Miriam Barrecheguren; Eulogio Pleguezuelos; Jesús Molina; José A Quintano; Miguel Roman-Rodríguez; Karlos Naberan; Carl Llor; Carlos Roncero; Marc Miravitlles Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-04-13
Authors: Christopher L Mosher; Michael G Nanna; Oliver K Jawitz; Vignesh Raman; Norma E Farrow; Samia Aleem; Richard Casaburi; Neil R MacIntyre; Scott M Palmer; Evan R Myers Journal: JAMA Netw Open Date: 2022-06-01
Authors: Bernardino Alcazar-Navarrete; Antonia Fuster; Patricia García Sidro; Juan Luis García Rivero; Beatriz Abascal-Bolado; Abel Pallarés-Sanmartín; Eduardo Márquez; Agustin Valido-Morales; Ana Boldova Loscertales; Francisco Javier Callejas-Gonzalez; Marta Palop; Juan Antonio Riesco; Rafael Golpe; Juan Jose Soler-Cataluña; Marc Miravitlles Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-10-28